Greater Regression of Electrocardiographic Left Ventricular Hypertrophy During Hydrochlorothiazide Therapy in Hypertensive Patients | Zendy

Peter M. Okin | Zendy; Darcy A. Hille | Zendy; Sverre E. Kjeldsen | Zendy; Lars Lindholm | Zendy; Jonathan M. Edelman | Zendy; Björn Dahlöf | Zendy; R DEVEREUX | Zendy

Open Access

Greater Regression of Electrocardiographic Left Ventricular Hypertrophy During Hydrochlorothiazide Therapy in Hypertensive Patients

Author(s) -

Peter M. Okin,

Darcy A. Hille,

Sverre E. Kjeldsen,

Lars Lindholm,

Jonathan M. Edelman,

Björn Dahlöf,

R DEVEREUX

Publication year - 2010

Publication title -

american journal of hypertension

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.009

H-Index - 136

eISSN - 1941-7225

pISSN - 0895-7061

DOI - 10.1038/ajh.2010.65

Subject(s) - medicine , atenolol , hydrochlorothiazide , losartan , left ventricular hypertrophy , cardiology , blood pressure , diastole , angiotensin ii

Treatment of hypertensive patients with a losartan-based regimen was associated with greater regression of electrocardiographic (ECG) left ventricular hypertrophy (LVH) than atenolol-based therapy in the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) study, independent of blood pressure (BP) changes. However, whether concomitant hydrochlorothiazide (HCTZ) therapy in >70% of LIFE patients was associated with greater regression of LVH independent of BP changes and whether this effect differed between treatment arms has not been examined.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research